Advertisement

Lifespan of immunosuppressed NMRI-mice is increased by deprenyl

  • H.-J. Freisleben
  • F. Lehr
  • J. Fuchs
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 41)

Summary

Immunosuppressed NMRI-mice (nu/nu) were raised and kept under germ-reduced conditions and fed with a germ-reduced diet (14 animals = controls). For another 14 mice 4 mg of selegiline were admixed to 10 kg of the diet. The 50% survival rate of the latter group was 160% from birth or 220% from the beginning of the study. The survival rate in weeks finally reached 350%, and the aerea under the curve 250%. The last mouse in the control group died at the age of 5 months, 2.5 months after the study was started; the last mouse in the selegiline group died at the age of 14.5 months, 1 year after the beginning of the study.

Keywords

Dopaminergic Neuron Premature Aging Increase Life Expectancy Immunosuppressed Mouse Extend Life Expectancy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Birkmayer W, Knoll J, Riederer P, Youdim MB, Hars V, Marton J (1985) Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson’s disease: a longterm study. J Neural Transm 64: 113–127.PubMedCrossRefGoogle Scholar
  2. Fortmeyer HP (1981) Thymusaplastische Maus (nu/nu), Thymusaplastische Ratte (rnu/rnu): Haltung, Zucht, Versuchsmodelle. Paul Parey, Berlin Hamburg.Google Scholar
  3. Halliwell B (1989) Oxidants and the central nervous system: some fundamental questions. Acta Neurol Scand 126: 23–33.CrossRefGoogle Scholar
  4. Knoll J (1989) The pharmacology of selegiline ((—)deprenyl). New aspects. Acta Neurol Scand 126: 83–91.CrossRefGoogle Scholar
  5. Kornhuber J, Konradi C, Mack-Burkhard F, Riederer P, Heinsen H, Beckmann H (1989) Ontogenesis of monoamine oxydase-A and-B in the human brain frontal cortex. Brain Res 499: 81–86.PubMedCrossRefGoogle Scholar
  6. Oldfield FF (1992) Free radicals, dopamine, levodopa and Parkinson’s disease. Free Radic Res Commun 16 [Suppl 1] Abstract 10.3.Google Scholar
  7. Salo PT, Tatton WG (1991) Deprenyl reduces death of motoneurons caused by axotomy. J Neurosci Res 31: 1–7.Google Scholar
  8. Tatton WG, Greenwood CE (1991) Rescue of dying neurons: a new action of deprenyl in MPTP parkinsonism. J Neurosci Res 30: 666–672.PubMedCrossRefGoogle Scholar
  9. Youdim MBH, Ben-Shachar D, Riederer P (1989) Is Parkinson’s disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration?. Acta Neurol Scand 126: 47–54.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • H.-J. Freisleben
    • 1
  • F. Lehr
    • 2
  • J. Fuchs
    • 2
  1. 1.Gustav-Embden-Zentrum der Biologischen ChemieKlinikum der Johann Wolfgang Goethe-UniversitätFrankfurt/MainFederal Republic of Germany
  2. 2.Zentrum der Dermatologie und VenerologieKlinikum der Johann Wolfgang Goethe-UniversitätFrankfurt am MainFederal Republic of Germany

Personalised recommendations